IMUX nears pivotal Phase III readouts for vidofludimus calcium in relapsing MS
IMUX says vidofludimus calcium is nearing pivotal Phase III readouts in relapsing MS. The oral therapy targets both inflammatory and neurodegenerative mechanisms, aiming to address unmet needs in efficacy and safety.